The Efficacy of Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery: a Study Protocol for a Prospective, Open-label ,Multi-center, Randomized, Controlled Trial in China
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Temozolomide (Primary) ; Vebreltinib (Primary) ; Antineoplastics
- Indications Glioblastoma
- Focus Therapeutic Use
- 22 Jan 2025 New trial record